Navigation Links
Personalized Pharmaceutical Systems Announces Sale of Angioedema Clinical Prediction Guide to Viropharma Incorporated
Date:11/16/2009

NEW YORK, Nov. 16 /PRNewswire/ -- Personalized Pharmaceutical Systems (PPS) today announced the sale of the Angioedema Clinical Prediction Guide to Viropharma Incorporated.

PPS is a clinical trial enrichment and market differentiation company which has developed advanced technology in phenomics to help drug companies identify the correct patients for their drugs, and as a result help patients get the right drug the first time. Through the use of its phenomic technology, PPS developed the Angioedema Clinical Prediction Guide to help emergency room physicians quickly differentiate amongst different types of angioedema (AE) that can be life-threatening.

Allergic angioedema is more common, and can be treated with antihistaminergic treatments. Hereditary Angioedema (HAE) is a rare form of AE seen in less than 1% of AE patients presenting to emergency rooms, and is not treatable with antihistaminergic treatments. Due to both the rareness of HAE and the complexity of differentiating amongst the various types of AE, the HAE patient is often misdiagnosed and treated inappropriately in the emergency room, increasing the risk of life-threatening airway compromise.

Correct diagnosis of HAE is known to take, on average, several years from a patient's first visit to an emergency room. Viropharma has licensed the Angioedema Clinical Prediction Guide and is currently considering a large-scale retrospective validation analysis. If validated, Viropharma may use the Angioedema Clinical Prediction Guide as a component of their medical education strategy to give physicians a means to recognize rarer forms of AE, and thereby accelerate the referral and diagnosis of HAE.

"We are extremely pleased with this opportunity for Viropharma to use our technology to accelerate the diagnosis of patients with this very severe disease. We look forward to the possibility of future collaboration and new opportunities to optimize Viropharma's clinical trial design, increase physician awareness, and maximize patient access," Dr. Paul Herscu, CEO, PPS.

About Personalized Pharmaceutical Systems LLC

Personalized Pharmaceutical Systems (PPS) is a cutting edge clinical trial enhancement and market differentiation company designed to dramatically reduce risk for pharmaceutical companies in both drug development and post-market entry phases. PPS novel enrichment technology utilizes inter-individual variability, that currently confounds drug trials, to enhance efficacy outcomes and/or significantly reduce risk of adverse effects. PPS technology effectively dissects diagnostic populations into treatment response correlated subgroups through the analysis of thousands of clinical indices measured against a continuum of environmental variables. While most clinical trials currently compare 40-50 clinical indices against clinical outcomes, PPS templates consider over 1000 indices mapped against a continuum of environmental variations and tested in thousands of patients over the past 15 years. This level of granularity brings a new level of precision to provide reliable determination of true clinical phenotype at the whole patient level. This technology creates new opportunity for success with compounds that are stalled or failing in current trials. PPS technology can be seamlessly incorporated into existing Phase II-IV trials.

SOURCE Personalized Pharmaceutical Systems


'/>"/>
SOURCE Personalized Pharmaceutical Systems
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Personalized Medicine - The Genomic Revolution in Cardiac Care
2. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
3. Biomarkers May Reduce the Need for Biopsies and Offer Personalized Care for Heart and Lung Transplant Patients
4. Studies Point to Benefits of Personalized Chemotherapy Dose Management in Colorectal Cancer
5. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
6. New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM(R)) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
7. Personalized Medicine Expert: Dont Fix It, Predict It
8. Personalized Medicine Killer Apps Will Transform Care Model
9. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
10. Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
11. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Research and ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" report ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, ... Structural electronics involves electronic and/or electrical components ... replacing dumb structures such as vehicle bodies or ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
Breaking Medicine News(10 mins):